Elagolix reduces menstrual bleeding from most common uterine tumors

November 09, 2018

DALLAS - Nov. 9, 2018 - A new oral drug significantly reduced menstrual bleeding for women with the most common gynecologic tumors in the United States - benign tumors that disproportionately affect African-Americans, an international clinical trial found.

In the five-country study, Elagolix reduced bleeding in more than 90 percent of premenopausal women who had heavy menstrual bleeding associated with fibroid tumors - noncancerous growths of the uterus known as uterine leiomyomas that often appear during childbearing years.

Surgery has traditionally been the gold standard for treatment, resulting in hysterectomy or myomectomy, so a nonsurgical option offers new hope, said Dr. Bruce Carr, Professor of Obstetrics and Gynecology at UT Southwestern Medical Center and lead author on the study appearing in the journal Obstetrics & Gynecology.

"There are no orally approved drugs to decrease bleeding and prevent anemia in women with these tumors," said Dr. Carr, Director of the Reproductive Endocrinology and Infertility Fellowship Program at UT Southwestern, who holds the Paul C. MacDonald Distinguished Chair in Obstetrics & Gynecology. "Now, there is a medical option for this devastating disease that affects up to 75 percent of women."

Prescribing hormone therapy together with the new drug prevented estrogen-deficiency induced side effects like hot flashes and bone loss, the researchers found.

Fibroid tumors can be associated with infertility, miscarriage, and early onset of labor and are the most common reason for hysterectomy worldwide, costing an estimated $2.2 billion in the U.S. alone. For women in their 40s and 50s, abnormal uterine bleeding also is the most common reason to see a gynecologist, and fibroids are one of the most common causes of the symptom.

Researchers examining health disparities of uterine fibroids found that 80 percent of African-American women and approximately 70 percent of white women will have uterine fibroids by age 50, although the tumors cause symptoms in only about a quarter to half of women who have them. Research in the Journal of Women's Health reported that African-American women:Researchers conducted the clinical trial at 86 sites in the United States, Puerto Rico, Canada, Chile, and the United Kingdom and involved the Mayo Clinic, Eastern Virginia Medical School, the University of Illinois, the Cleveland Clinic, Mercy Health Osteoporosis and Bone Health Services, Augusta University, and The George Washington University in Washington, D.C., along with the maker of the new drug (elagolix), AbbVie Inc. Dr. Carr received research support from AbbVie and Agile Therapeutics and served on the Repros Therapeutics Data and Safety Monitoring Board.
-end-
About UT Southwestern Medical Center

UT Southwestern, one of the premier academic medical centers in the nation, integrates pioneering biomedical research with exceptional clinical care and education. The institution's faculty has received six Nobel Prizes, and includes 22 members of the National Academy of Sciences, 17 members of the National Academy of Medicine, and 15 Howard Hughes Medical Institute Investigators. The faculty of more than 2,700 is responsible for groundbreaking medical advances and is committed to translating science-driven research quickly to new clinical treatments. UT Southwestern physicians provide care in about 80 specialties to more than 105,000 hospitalized patients, nearly 370,000 emergency room cases, and oversee approximately 2.4 million outpatient visits a year.

UT Southwestern Medical Center

Related Tumors Articles from Brightsurf:

A viable vaccine for tough tumors
While immunotherapies work well for some cancers, others are immune-resistant and condemn patients to the severe side effects of long-term chemo treatment.

Women could conceive after ovarian tumors
Women receiving fertility-sparing surgery for treatment of borderline ovarian tumours were able to have children, a study from Karolinska Institutet in Sweden published in Fertility & Sterility shows.

Attacking tumors from the inside
A new technology that allows researchers to peer inside malignant tumors shows that two experimental drugs can normalize aberrant blood vessels, oxygenation, and other aspects of the tumor microenvironment in non-small cell lung cancer (NSCLC), helping to suppress the tumor's growth and spread, UT Southwestern researchers report.

Directing nanoparticles straight to tumors
Modern anticancer therapies aim to attack tumor cells while sparing healthy tissue.

A solid vaccine for liquid tumors
Acute myeloid leukemia (AML) is a deadly blood cancer that kills most of its victims within five years.

Evolutionarily novel genes work in tumors
A team of scientists from Peter the Great St. Petersburg Polytechnic University studied the evolutionary ages of human genes and identified a new class of them expressed in tumors -- tumor specifically expressed, evolutionarily novel (TSEEN) genes.

Identification of all types of germ cells tumors
Germ cell tumors were considered very heterogeneous and diverse, until recently.

Laser light detects tumors
A team of researchers from Jena presents a groundbreaking new method for the rapid, gentle and reliable detection of tumors with laser light.

Better prognosticating for dogs with mammary tumors
For dogs with mammary tumors, deciding a course of treatment can depend on a variety of factors, some of which may seem to contradict one another.

The evolution of brain tumors
Scientists from the German Cancer Research Center found in a recent study that only three different genetic alterations drive the early development of malignant glioblastomas.

Read More: Tumors News and Tumors Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.